Acrivon provides pipeline and AP3 update, reports cash runway into Q4 2024

Acrivon Therapeutics, Inc.

Hosted virtual investor event on May 1, 2023 with updated corporate presentation.
Disclosed cash and marketable securities as of March 31, 2023 (amount not specified in filing).
Confirmed cash runway extends into at least Q4 2024.
Presentation highlights progress on AP3 precision proteomics platform and pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.